Research programme: diketopiperazine compounds - Neuren Pharmaceuticals

Drug Profile

Research programme: diketopiperazine compounds - Neuren Pharmaceuticals

Alternative Names: NNZ-2591

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuren Pharmaceuticals
  • Class Cyclic peptides; Piperazines; Small molecules
  • Mechanism of Action Cell death inhibitors; Immunomodulators; Neuropeptide receptor modulators; Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders; Parkinson's disease; Stroke
  • No development reported Multiple sclerosis

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for preclinical development in Multiple-sclerosis in Australia (PO)
  • 05 Dec 2017 Neuren Pharmaceuticals receives patent allowance for NNZ 2591 in USA
  • 30 Nov 2015 Neuren has patent protection for NNZ 2591 in European Union and has an international patent pending for NNZ 2591
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top